July 13, 2016

VALUATION WATCH: Overvalued stocks now make up 44.97% of our stocks assigned a valuation and 14.72% of those equities are calculated to be overvalued by 20% or more. Six sectors are calculated to be overvalued.

If you cannot display this bulletin properly, GO HERE

Prime Time

FivePrime Therapeutics Is ValuEngine Top Stock

ValuEngine tracks more than 7000 US equities, ADRs, and foreign stock which trade on US exchanges as well as @1000 Canadian equities.  When EPS estimates are available for a given equity, our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient--an academic exercise to be sure, but one which allows for useful comparisons between equities, sectors, and industries. Using our Valuation Model, we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe.

We combine all of the equities with a valuation calculation to track market valuation figures and use them as a metric for making calls about the overall state of the market.  Two factors can lower these figures-- a market pullback, or a significant rise in EPS estimates.

We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.

So, for today's bulletin we used our website's advanced screening functions to search for the top-rated STRONG BUY US stock with valuation data that meets minimum liquidity requirements. FivePrime Therapeutics (FPRX) currently leads our universe.

Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.

ValuEngine continues its STRONG BUY recommendation on FIVEPRIME THERA for 2016-07-12. Based on the information we have gathered and our resulting research, we feel that FIVEPRIME THERA has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Momentum.

You can download a free copy of detailed report on Five Prime Therapeutics from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	45.13	1.65%
3-Month	46.09	3.81%
6-Month	46.76	5.31%
1-Year	53.26	19.97%
2-Year	48.26	8.69%
3-Year	44.26	-0.32%

Valuation & Rankings
Valuation	4.28% undervalued	Valuation Rank(?)	53
1-M Forecast Return	1.65%	1-M Forecast Return Rank	100
12-M Return	69.92%	Momentum Rank(?)	95
Sharpe Ratio	0.51	Sharpe Ratio Rank(?)	85
5-Y Avg Annual Return	41.80%	5-Y Avg Annual Rtn Rank	99
Volatility	82.06%	Volatility Rank(?)	19
Expected EPS Growth	-139.23%	EPS Growth Rank(?)	3
Market Cap (billions)	1.11	Size Rank	67
Trailing P/E Ratio	5.12	Trailing P/E Rank(?)	98
Forward P/E Ratio	n/a	Forward P/E Ratio Rank	n/a
PEG Ratio	n/a	PEG Ratio Rank	n/a
Price/Sales	2.90	Price/Sales Rank(?)	33
Market/Book	2.59	Market/Book Rank(?)	43
Beta	3.61	Beta Rank	3
Alpha	0.45	Alpha Rank	94

DOWNLOAD A FREE SAMPLE OF OUR FIVEPRIME THERAPUETICS (FPRX) REPORT BY CLICKING HERE

ValuEngine Market Overview

ValuEngine Sector Overview